Ningetinib-Gefitinib Interaction: CYP1A1 and Efflux Transporter Data

A study investigates the drug interaction mechanism between the tyrosine kinase inhibitors ningetinib and gefitinib in non-small cell lung cancer patients. In vitro models and patient data show CYP1A1 is primarily responsible for forming the M1 metabolite, which gefitinib strongly inhibits. The research, authored by Lu Liu from the Chinese Academy of Sciences, identifies M1 as a substrate for efflux transporters P-gp, BCRP, and MRP2.

Use Cases

• Model drug-drug interaction mechanisms based on in vitro metabolic and transport data.
• Analyze the pharmacokinetic impact of CYP1A1 inhibition on metabolite exposure.
• Investigate the role of efflux transporters like P-gp and BCRP in metabolite distribution.
• Study the safety and efficacy implications of co-administering tyrosine kinase inhibitors.

Strengths

• Includes in vitro experimental data on enzyme inhibition with a reported Ki value of 0.095 μM.
• Investigates multiple efflux transporters (P-gp, BCRP, MRP2) and their substrates/inhibitors.
• Uses deuterated metabolite (D6-M1) and mouse models to study pharmacokinetics.

Limitations

• Row count and dataset size are unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Last update date is unknown; freshness unverified.

Provenance

Source

Chinese Academy of Sciences

Collection Method

In vitro models, patient recruitment, and mouse pharmacokinetic studies.